Janssen Biotech, a company of Johnson & Johnson, owns the patent, which relates to the company's arthritis drug Remicade
NYSE: PFE), with South Korea-based biopharmaceutical company Celltrion Healthcare, has released secondary outcomes data from the phase III trial of Inflectra in Crohn's Disease (CD) that show that switching patients with CD to Inflectra (infliximab CT-P13) from Remicade
(infliximab) led to comparable efficacy, safety, and tolerability to treatment with Remicade
over a 24 week period, the company said.
, Renflexis will come with a boxed warning and a Medication Guide that describes important information about its uses and risks, which include serious infections, lymphoma and other malignancies, liver injury, blood problems, lupuslike syndrome, psoriasis, and in rare cases, nervous system disorders.
It was reported yesterday that the statement of objections is for the Competition and Markets Authority's provisional decision that the company operated an anti-competitive discount scheme for its medicine, Remicade
The Competition and Markets Authority (CMA) said MSD appears to have abused its marketleading position by discounting the rheumatoid arthritis medicine Remicade
to such an extent that it is holding back competition from similar versions sold by other firms.
s lower-price alternative to autoimmune disease drug Remicade
doesn't infringe a Johnson & Johnson (J&J) patent on the blockbuster drug.
NHS England has decided not to recommend routine use of drugs Humira and Remicade
for patients with the severe eye condition.
The approval of revolutionary biological therapies, including Enbrel, Remicade
and Humira, for the treatment of RA patients that are refractory to MTX has triggered unparalleled growth in the market.
, has gained a significant patent share of the aGVI ID patient group, as it is one of the few drugs that are efficient in GVHD with G1 involvement.
At issue is whether Merck's $41 billion acquisition of Schering-Plough last year constituted a "change of control" at Schering that would cede the lucrative overseas Remicade
and Simponi rights back to J&J, which owns the drugs and sells them in the United States.
is given by intravenous (IV) infusion about every eight weeks.
Horsham, PA) and Schering-Plough Corporation (Kenilworth, NJ) have revised their 1998 distribution agreement regarding the development, commercialization and distribution of both REMICADE
(infliximab), an anti-tumor necrosis factor (anti-TNF) alpha therapy for chronic inflammatory disorders, and golimumab, Centocor's next-generation, human, anti-TNF alpha therapy, which is currently in Phase 3 trials.